Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$104.96 USD

104.96
199,146

-1.82 (-1.70%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $105.03 +0.07 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Philips (PHG) Inks 7-Year Partnership With Northwell Health

by Zacks Equity Research

Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.

Zacks Equity Research

Philips (PHG) Drives Health Care Prospects With New Solutions

by Zacks Equity Research

Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.

Zacks Equity Research

Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group

by Zacks Equity Research

Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.

Zacks Equity Research

Here's Why You Should Retain HCA Healthcare (HCA) Stock Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.

Debanjana Dey headshot

4 Promising Stocks From a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

Zacks Equity Research

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Addus HomeCare (ADUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Alcon (ALC) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes Addus HomeCare (ADUS) a New Buy Stock

by Zacks Equity Research

Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Addus HomeCare (ADUS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 14.43% and 0.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Option Care (OPCH) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Addus HomeCare (ADUS) Reports Next Week: What to Expect

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant

by Zacks Equity Research

Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.

Zacks Equity Research

4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry

by Zacks Equity Research

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.

Zacks Equity Research

Addus HomeCare (ADUS) Tops Q3 Earnings Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.08% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Addus HomeCare (ADUS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Addus HomeCare (ADUS) stock based on the movements in the options market lately.

Debanjana Dey headshot

3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.

Zacks Equity Research

Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.11% and 1.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Addus HomeCare (ADUS) Reports Next Week: What You Should Expect

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Addus HomeCare (ADUS) Tops Q1 Earnings Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.32% and 0.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Addus HomeCare (ADUS) Stock Jumps 6.5%: Will It Continue to Soar?

by Zacks Equity Research

Addus HomeCare (ADUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.